Shire plc Total Voting Rights

 
TIDMSHP 
 
 
 
   Total Voting Rights 
 
   November 1, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company"), 
in accordance with 5.6.1R of the Financial Conduct Authority's (the 
"FCA") Disclosure Guidance and Transparency Rules, notifies the market 
of the following: 
 
   As at October 31, 2018, the Company's issued ordinary share capital 
comprised 914,818,708 ordinary shares of 5 pence each with voting rights 
and a further 7,357,283 ordinary shares held in treasury. 
 
   Therefore, the total number of voting rights in the Company is 
914,818,708. This is the figure which should be used by shareholders as 
the denominator for the calculations by which they will determine if 
they are required to notify their interest in, or a change to their 
interest in, the Company under the FCA's Disclosure Guidance and 
Transparency Rules. 
 
   Sarah Rixon 
 
   Senior Company Secretarial Assistant 
 
   For further information please contact: 
 
 
 
 
Investor Relations 
Christoph Brackmann   christoph.brackmann@shire.com   +41 41 288 41 29 
Sun Kim               sun.kim@shire.com                +1 617 588 8175 
Scott Burrows         scott.burrows@shire.com          +41 41 288 4195 
 
Media 
Katie Joyce           kjoyce@shire.com                 +1 781 482 2779 
 
 
 
   NOTES TO EDITORS 
 
   About Shire 
 
   Shire is the global biotechnology leader serving patients with rare 
diseases and specialized conditions. We seek to push boundaries through 
discovering and delivering new possibilities for patient communities who 
often have few or no other champions. Relentlessly on the edge of what's 
next, we are serial innovators with a diverse pipeline offering fresh 
thinking and new hope. Serving patients and partnering with healthcare 
communities in over 100 countries, we strive to be part of the entire 
patient journey to enable earlier diagnosis, raise standards of care, 
accelerate access to treatment, and support patients. Our diverse 
portfolio of therapeutic areas includes Immunology, Hematology, Genetic 
Diseases, Neuroscience, Internal Medicine, and Ophthalmics. 
 
 
 
   Championing patients is our call to action - it brings the opportunity - 
and responsibility - to change people's lives. 
 
   www.shire.com

(END) Dow Jones Newswires

November 01, 2018 07:00 ET (11:00 GMT)

Shire Ads Rep 3 (LSE:0L60)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024